Human microdosing for the prediction of patient response
Bioanalysis March 1, 2010 DOI: 10.4155/bio.10.3 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Topics | Microdosing |
| Key findings | Argues that microdosing, originally developed in molecular toxicology, is now being applied to medical diagnostics, with recent efforts focusing on prognostic and predictive diagnostics to improve disease detection and treatment. |
Abstract
Microdosing allows study of the behavior of drugs via the administration of doses so low they are unlikely to produce whole-body effects, but of sufficient concentration to allow the determination of absorption, distribution, metabolism and excretion (ADME). Microdosing was recently reviewed elsewhere [1,2]; although most effort to date has focused on pharmacokinetic (PK) predictions to accelerate drug development, microdosing was born out of molecular toxicology research [3-10] and is now extending to medical diagnostics applications. Here, we provide a brief overview of microdosing for drug development, followed by a description of recent efforts to implement prognostic and predictive diagnostics aimed at improving detection and treatment of human disease.